Leads Biolabs’ Phase IIb opamtistomig study selected for ESMO 2026

Company says its pivotal registrational Phase IIb study of opamtistomig (LBL-024) was selected as an ESMO 2026 late-breaking abstract, and three studies were selected for proffered paper presentations.